Lifevantage Corporation (Delaware) (LFVN) exhibits 80.4% gross margins and 29.2% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 5.5x enterprise multiple and 4.8% implied options volatility.
Sustained 80.4% gross profitability converts into 5.3% operating margin and 29.2% ROIC, outpacing sector cost of capital.
ROIC: 29.2% // GM: 80.4%YoY revenue trajectory of +14.2% paired with 14.22% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +14.2% // FCF YLD: 14.22%Altman Z-Score of 3.98 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.98 // F-SCORE: 8/9Trading at 7.5x trailing P/E (6.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 7.5x // EV/EBITDA: 5.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $5.88 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 4.3% net margins.
NET MARGIN: 4.3% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for LFVN & activate live FRED threshold breach alerts.